Hematology

Latest News

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.

Gloved hands holding ALL blocks | Image credit: Sviatlana - stock.adobe.com
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

July 30th 2025

Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com
Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

July 29th 2025

Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

July 28th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Site Logo
January 27th 2017

Coverage of 2016 American Society of Hematology Meeting Available From AJMC®

The American Journal of Managed Care® presents its annual special issue of Evidence-Based Oncologyâ„¢ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.
Stuart Genschaw Discusses His Practice's Transition Towards Implementing the OCM
January 8th 2017

Stuart Genschaw Discusses His Practice's Transition Towards Implementing the OCM

As Cancer & Hematology Centers of Western Michigan starts to participate in the Oncology Care Model (OCM), it has dedicated its resources to understanding the model and analyzing data, said Stuart Genschaw, executive director of the Cancer & Hematology Centers of Western Michigan. Throughout this process, however, the practice’s main focus is always on “providing great care” to its patients.
Site Logo
March 15th 2016

Clinical Significance of Neutropenia in Routine Complete Blood Cell Counts

Priyam Vora
A new study found the prevalence of neutropenia in routine complete blood cell counts directly associated with viral infections, hematological malignancies, and mortality.
This Week in Managed Care: December 12, 2015
December 12th 2015

This Week in Managed Care: December 12, 2015

This week in managed care, an analysis found the penalty for being uninsured will exceed the cost of insurance for most Americans in 2016, thousands met for the annual meeting of the American Society of Hematology, and Horizon Blue Cross Blue Shield's OMNIA plan gets good news and bad news in New Jersey.
Alex Bastian Strives to Define Value in Care Better
December 16th 2014

Alex Bastian Strives to Define Value in Care Better

In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.
Site Logo
December 8th 2014

Giora Sharf Discusses Ways to Represent the CML Patient Voice

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.
Site Logo
December 8th 2014

Dr Susanne Saussele Defines When Patients With CML Should Change Therapy

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.
Site Logo
December 8th 2014

Evaluating Safety, Efficacy, and Outcomes of TKIs in CML

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.
Site Logo
December 8th 2014

Jan Geissler Explains Differing Perceptions for Living With CML

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.
Site Logo
December 8th 2014

Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.
Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML
December 8th 2014

Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML

The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.
Healthcare Costs in Need of Solutions: Experts at ASH Agree
December 7th 2014

Healthcare Costs in Need of Solutions: Experts at ASH Agree

While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.
Site Logo
August 23rd 2014

MMRF Efforts Attack the Disease From Every Angle; "Transformation" on the Horizon

Mary K. Caffrey
Site Logo
June 3rd 2014

Press Release: Advances in Multiple Myeloma Therapy Extend Survival for Patients, Raising Cost Concerns

The American Journal of Managed Care convened a panel of experts to discuss advances and challenges in treating multiple myeloma, which has seen longer survival rates since the arrival of bortezomib and thalidomide.
Site Logo
May 16th 2014

Nivolumab Gets Breakthrough Designation for Hodgkin's Lymphoma

BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.
From Laboratory to Licensure: Preclinical Phase Critical in Creating New Targeted Therapies
December 10th 2013

From Laboratory to Licensure: Preclinical Phase Critical in Creating New Targeted Therapies

One billion dollars. That can be the list price for bringing a new cancer-fighting agent from preclinical design through approval by the US Food and Drug Administration, according to Michael R. Grever, MD, of the Ohio State University.
As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues
December 10th 2013

As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues

Treating lymphoma today starts with an understanding of what is being treated, and the revolution in genetic profiling lets clinicians do that with more precision than ever.
Treating the Signs of Multiple Myeloma Before it Starts
December 8th 2013

Treating the Signs of Multiple Myeloma Before it Starts

Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission especially if stem cell transplantation is a possibility against the toxicity of the treatment itself.
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever
December 8th 2013

Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever

With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.
Site Logo
October 23rd 2013

Challenges in Oncology Practice

AJMC Staff
Site Logo
August 2nd 2013

ASH Releases Analysis on Impact of Medicare Proposed Rules on Hematologists

On July 8, 2012, the Centers for Medicare & Medicaid Services (CMS) released two major Medicare proposed rules impacting payment for physician and hospital outpatient services in 2014. ASH will submit comments to CMS on the proposed rules by the September 6 deadline and would like to incorporate feedback from the Society's practice-based members.
PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD
December 11th 2012

PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD

Henri Stanton
At the 54th Annual Meeting of the American Society of Hematology, John Radford, MD, reported the results of the United Kingdom RAPID trial, in which PET-directed therapy provided an opportunity to avoid involved field radiotherapy, the current standard of care following abbreviated chemotherapy in early stage Hodgkin's lymphoma.
Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD
December 10th 2012

Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD

Bonnie Gillis
Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem cell transplantation reduced the cumulative incidence of graft-versus-host disease in a phase I/II trial reported at the 54th Annual Meeting of the American Society of Hematology.
Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma
December 9th 2012

Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma

Bonnie Gillis
An investigational, weekly, oral proteosome inhibitor called MLN9708 achieved excellent response rates when combined with lenalidomide and dexamethasone as up-front treatment of newly diagnosed patients with multiple myeloma, according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology.
Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL
December 9th 2012

Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL

Bonnie Gillis
Ibrutinib, an investigational Bruton's tyrosine kinase inhibitor, achieved excellent results in clinical trials of patients with chronic lymphocytic leukemia (CLL) presented at the 54th Annual Meeting of the American Society of Hematology.
Extending Anticoagulation With Apixaban Reduces Recurrent VTE
December 9th 2012

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

Henri Stanton
Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.
<1
...
232425262728>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo